Early mechanistic study combining in vitro and animal models with pathway inhibitor validation, but lacking human clinical data and using surrogate endpoints of cardiac function and cell viability.
Rigorous systematic review and meta-analysis of 20 RCTs with pre-registration, low risk of bias in majority of included studies, and high certainty of evidence for primary anthropometric outcomes (BMI, weight), though effect sizes are modest and direct body composition changes were not significant.
Sound preclinical study in mice demonstrating metabolic benefit of a natural compound via plausible signaling pathways, but lacks human evidence and relies on surrogate endpoints and mechanistic markers rather than clinical outcomes.
Preclinical mechanistic study in animal models and cell cultures demonstrating pathway involvement; lacks clinical efficacy data, human trials, or quantified effect sizes to support clinical translation.